# RedirecTT-1 (NCT04586426)

> A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04586426
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Talquetamab; Teclistamab
- Enrollment: 228
- Primary outcome: Part 1: Number of Participants with Dose Limiting Toxicity (DLT)
- Primary outcome: Part 1: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
- Primary outcome: Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability
- Primary outcome: Part 2: Number of Participants with Adverse Events and SAEs by Severity
- Primary outcome: Part 3: Overall Response Rate (ORR)

## Commentary we found

- X threads: 49
- YouTube: 18
- Podcasts: 13
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=redirectt-1-nct04586426

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04586426", "email": "<work email>"}; the inbox owner confirms by the emailed link.